Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAMK2D | Q13557 | 1/20 | 0.41 |
| ▸ | AXL | P30530 | 5/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 7/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 6/20 | 0.38 |
| ▸ | CDK4 | P11802 | 4/20 | 0.38 |
| ▸ | CCND1 | P24385 | 4/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.38 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.38 |
| ▸ | FGFR4 | P22455 | 3/20 | 0.38 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.38 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.36 |
| ▸ | INSR | P06213 | 1/20 | 0.36 |
| ▸ | IGF1R | P08069 | 1/20 | 0.36 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.36 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | AURKA | O14965 | 2/20 | 0.35 |
| ▸ | SRC | P12931 | 2/20 | 0.35 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15035286 | 0.93 | AXL (0.41) | CAMK2DAXLEGFRCDK2CCNA2 | |
| SCHEMBL15035499 | 0.84 | TNK2 (0.44) | AXLEGFRSRCTNK2 | |
| SCHEMBL15041353 | 0.84 | CAMK2D (0.45) | CAMK2DAXLEGFRCDK2CCNA2 | |
| SCHEMBL15041808 | 0.80 | CDK4 (0.41) | CAMK2DAXLEGFRCDK2CCNA2 | |
| SCHEMBL15041575 | 0.79 | CDK2 (0.40) | CAMK2DAXLEGFRCDK2CCNA2 | |
| SCHEMBL15041301 | 0.79 | CAMK2D (0.41) | CAMK2DAXLEGFRCDK2CCNA2 | |
| SCHEMBL15041602 | 0.77 | CAMK2D (0.39) | CAMK2DAXLEGFRCDK2CCNA2 | |
| SCHEMBL15035500 | 0.76 | CAMK2D (0.43) | CAMK2DAXLEGFRCDK2CCNA2 | |
| SCHEMBL15041585 | 0.76 | CDK2 (0.39) | CAMK2DAXLEGFRCDK2CCNA2 | |
| SCHEMBL15041617 | 0.76 | CDK4 (0.49) | EGFRCDK2CCNA2CDK4CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | PAK5, PAK2, PAK6 | CAMK2D 469/4885AXL 1075/4885EGFR 737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.